The orphan nuclear receptors, steroidogenic factor 1 (SF-1) and DAX-1, are involved in gonadotroph differentiation, and SF-1 has been shown to activate the LH-␤ and glycoprotein hormone ␣-subunit (␣GSU) gene promoters. Pituitary adenomas from 34 patients [13 somatotroph tumors, 4 prolactinomas, and 17 clinically nonfunctioning pituitary adenomas (NFPAs)] were enzymatically dispersed and cultured in vitro for 48 h. Tissue culture medium was collected and assayed for LH, FSH, and ␣GSU; messenger RNA was extracted from adherent cells, and expression of SF-1 and DAX-1 messenger RNA was determined by RT-PCR and verified by direct DNA sequencing. The presence of DAX-1 protein in tumor tissue was confirmed by immunocytochemistry.
T HE MATURE ANTERIOR pituitary gland contains
specific hormone-producing cell types that develop from pluripotential progenitor cells (1) . Differentiated cell types emerge in a precise spatial and temporal pattern, with their development being regulated by several tissueand cell-specific transcription factors (2) . For example, a tissue-specific POU domain factor Pit-1 is required for terminal differentiation, growth, and survival of somatotrophs, lactotrophs, and thyrotrophs (3) and also regulates the expression of the cell specific genes, GH, PRL, and TSH-␤-subunit (4) .
Two members of the nuclear receptor superfamily, steroidogenic factor 1 (SF-1) and DAX-1, have recently been shown to play important roles in pituitary gonadotroph differentiation and regulation of gonadotroph-specific hormone genes (5) . SF-1 (also called Ad4BP) expression was first demonstrated in adrenal and gonadal cells but was subsequently identified in the pituitary, with localization to the gonadotroph (6, 7) . SF-1 is important for the development and differentiation of pituitary gonadotrophs (6) and has been shown to regulate both the glycoprotein hormone ␣-subunit gene (␣GSU) (7) and the LH ␤-subunit gene (LH-␤) (8) . Mice with disruption of the gene encoding SF-1 (ftz-f1) exhibit adrenal hypofunction, gonadal agenesis, and phenotypic XY sex reversal (9) . Like SF-1, DAX-1 also plays a role in adrenal and gonadal development and was first isolated by positional cloning from subjects with X-linked adrenal hypoplasia congenita (10) . Affected (male) individuals with DAX-1 gene mutations present with adrenal hypofunction at birth and gonadotropin deficiency at the time of expected puberty (11) . Conversely, duplication of the DAX-1 gene leads to male-to-female sex reversal (12) . SF-1 and DAX-1 share spatial and developmental patterns of expression (13) , and their mutual involvement in the development of the adrenal and gonadal axes suggested that SF-1 and DAX-1 might interact in the expression of tissue-specific genes. SF-1 has been shown to regulate DAX-1 expression (5, 14) , and DAX-1 may regulate its own expression by acting to inhibit SF-1-mediated expression (15) . DAX-1 is thought to oppose the transcriptional effects of SF-1 by interacting directly with SF-1 and recruiting corepressor molecules (16) .
Human pituitary adenomas are monoclonal expansions of anterior pituitary cells and, as such, represent a potentially useful model for the investigation of the transcriptional control of gene expression. A number of investigators have examined expression of SF-1 messenger RNA (mRNA) and protein in human pituitary adenomas (17, 18) and have concluded that SF-1 expression correlates with the expression of gonadotropins (17) and is restricted to cells derived from gonadotroph lineages (18) . One group has examined DAX-1 mRNA expression in pituitary adenomas and has shown that, in the majority of tumors, DAX-1 is expressed in parallel with SF-1 (19) . To date, no studies have examined expression of SF-1 and DAX-1 in relation to tumorous hormone secretion in vitro. The ␣GSU gene is regulated by SF-1 in gonadotrophs, whereas the transcription factors responsible for ␣GSU expression in thyrotrophs are less clearly defined but may include Msx-1 and Pitx-1 (20, 21) . However, ␣GSU is secreted from tumors other than gonadotroph and thyrotroph adenomas and is a frequent finding in plurihormonal tumors presenting with acromegaly (22) (23) (24) (25) ; the mechanisms involved in the apparently aberrant expression of ␣GSU in these plurihormonal tumors is not defined. In addition to ␣GSU, plurihormonal tumors have been shown to express gonadotropin and TSH ␤-subunits (25, 26) . We were therefore interested in examining the pattern of SF-1 and DAX-1 expression in relation to the secretion of ␣GSU and the gonadotropins, LH and FSH, both in adenomas of gonadotroph and somatotroph origin.
Materials and Methods

Clinical details and patient selection
Pituitary tumors were collected from 56 patients at the time of transsphenoidal adenomectomy. Tissues were divided, at the time of surgery, for diagnostic histological studies and for tissue culture. All subjects gave informed consent, at the time of operation, for surgical specimens to be used for diagnostic and research purposes.
Acromegaly was diagnosed on the basis of persistently measurable GH and inadequate suppression of GH on administration of an oral glucose load. Those patients with PRL-secreting macroadenomas represented a subset of patients with hyperprolactinemia that had not responded to treatment with dopamine agonist therapy and who required debulking surgery before external beam radiotherapy. Patients who presented because of mass effect, without clinical features of anterior pituitary hormone excess and without laboratory evidence of tumor-derived hormone hypersecretion, were classified as having clinically nonfunctioning pituitary adenomas (NFPAs).
After surgery, confirmation of the clinical diagnosis was obtained by light microscopy and immunocytochemistry. Tumors from patients with NFPAs were examined by immunocytochemistry to exclude low-grade GH, PRL, or ACTH secretion. Tumors were excluded from the series if significant normal pituitary tissue was present on microscopy, if microscopy suggested an alternative histological diagnosis, if the tissue seemed necrotic, or if histological data were unavailable.
Morphology and immunocytochemistry
All tumors were examined by standard hematoxylin and eosin, reticulin, and periodic acid Schiff stains, and routine immunostaining was performed for GH, PRL, ACTH, TSH-␤, LH-␤, FSH-␤ (antibodies against the whole molecule obtained from BioGenex Laboratories, Inc. Ltd., Berkshire, UK), and ␣GSU (rabbit polyclonal, UCB Bioproducts Braine-L'alleud, Belgium), using a standard streptavidin-biotin horseradish peroxidase method and previously optimized antigen recovery (27) . The amount of hormone positivity in all tumors was initially assessed and quantified by means of a three-point scale (-, negative or scattered cells representing less than 10%; ϩ, 10 -50% positive; ϩϩ, Ͼ50% positive). Immunostaining for the presence of transcription factor antigen was also performed in tumors where sufficient tissue was available, using an antibody directed against DAX-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). DAX-1 antiserum was used at a dilution of 1:500, pretreated in a microwave for 10 min in a 0.01-mol/L citrate buffer at pH6. Normal pituitary tissue from surgical specimens was used as a positive control; and fresh biopsy specimens from skeletal muscle, heart, liver, and kidney were used as negative controls. A rabbit polyclonal IgG, raised against the DNA binding domain of a bacterially expressed mouse SF-1-GST fusion protein, was used to immunostain for SF-1 (Upstate Biotechnology, Inc., Lake Placid, NY). The antibody was stored at Ϫ20 C and used at a 1:1000 dilution.
Pituitary tumor cell culture
Pituitary adenoma tissue was transported to the laboratory in DMEM containing 10% (vol/vol) heat-inactivated FCS, 0.06 g/L penicillin, 0.1 g/L streptomycin, and 2.5 g/L fungizone (Life Technologies, Inc., Paisley, Strathclyde, UK), hereafter referred to as culture medium. Tumor tissue was dispersed enzymatically with trypsin, as described previously (27) . Dispersed cells were harvested by centrifugation, washed once, and subsequently resuspended in culture medium. Cell viability was assessed using trypan blue exclusion and was more than 90% of cells in all of the tumors studied after cell dispersion. Cell yield from each tumor varied from 1-15 ϫ 10 6 cells. The cells were plated in 6-well plates at approximately 1 ϫ 10 6 cells per well in 4 mL medium. Cultures were incubated at 37 C in a humidified atmosphere of 95% air-5% CO 2 , for 48 h, to allow cell attachment to occur, after which time the medium was collected and assayed for basal hormone secretion as described below. Adherent cells were lysed with a buffered guanidinium thiocyanate solution and stored at Ϫ70 C before mRNA extraction (see below).
mRNA analysis
Cell extract from cultured cells was thawed on ice and centrifuged to remove cell debris. mRNA was isolated using the QuickPrep micro mRNA purification kit (Pharmacia Biotech, St. Albans, Herts, UK), which uses oligo (dT) cellulose to extract poly (A) mRNA. After washing in low-and high-salt buffer [10 mmol/L Tris-HCl (pH 7.5), 1 mmol/L EDTA, and NaCl (0.1 mol/L or 0.5 mol/L respectively)], the mRNA was eluted in 10 mmol/L Tris-HCl and 1 mmol/L EDTA and precipitated with glycogen (0.25 g/L), 0.25 mol/L potassium acetate, and 95% ethanol. After centrifugation, the RNA pellet was washed with 75% ethanol and allowed to dry before being resuspended in diethylpyrocarbonatetreated water. Quantitation was performed by optical density measurement at 260nm, with approximately 0.5-1.0 g mRNA being recovered from 10 6 cells.
RT-PCR
RT was performed using the First Strand complementary DNA (cDNA) synthesis kit (Pharmacia Biotech), which uses Moloney murine leukemia virus reverse transcriptase and a NotI-d(T) 18 bifunctional primer. RT was also performed on each RNA sample in the absence of Moloney murine leukemia virus reverse transcriptase. PCR carried out on this resultant RT reaction generated no PCR product, confirming the absence of genomic DNA contamination.
PCR was carried out using the equivalent of 0.1 g mRNA in a total reaction vol of 50 L, and a so-called hot-start technique was employed. To reduce the variability between samples, PCR components were premixed before addition to individual PCR tubes. The 50 L reaction mixture contained 0.2 mmol/L deoxynucleotide triphosphate, 5 L 10-fold concentrated PCR buffer, 5 L cDNA, and 100 pmol of either Pit-1, SF-1, or DAX-1 primers. Primers used were as follows: Pit-1: 5Ј-AGTGCTGCCGAGTGTCTACCA-3Ј (forward), 5Ј-TTTCTTTTCCTTTCATTTGCT-3Ј (reverse), generating a fragment of 560 bp (28); SF-1: 5Ј-GCATCTTGGGCTGCCTGCAG-3Ј (forward), 5Ј-CCTTGCCGTGCTGGACCTGG-3Ј (reverse), generating a fragment of 230 bp (17); DAX-1: 5Ј-AAGGAGTACGCCTACCTCAA-3Ј (forward), 5Ј-TCCATGCTGACTGTGCCGAT-3Ј (reverse), generating a fragment of 251 bp (13) . All primers were set on different exons of each gene so that they spanned an intron. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used to verify the integrity of RNA from each specimen, using primers from CLONTECH Laboratories, Inc. (Cambridge, UK) in each PCR and generated a 986-bp fragment. The PCR mixture was heated to 94 C for 3 min and cooled before addition of 2.5 U Taq polymerase (Roche Molecular Biochemicals, Lewes, East Sussex, UK), followed by 30 cycles of denaturation at 94 C for 30 sec, annealing at appropriate temperatures (Pit-1, 60 C; SF-1, 60 C; DAX-1, 55 C) for 30 sec, and extension at 72 C for 45 sec. Controls with water replacing template were included in all experiments. PCR products were separated by electrophoresis using 1.6% agarose gels stained with 0.5 g/mL ethidium bromide and examined under ultraviolet light for the presence of a band of the expected size. HincII-digested DNA was run in parallel as a molecular weight marker. Transcription factor expression was examined in one tumor before dispersal, with the remainder of the tissue being dispersed as de-scribed above. The pattern of transcription factor expression was identical in both mRNA samples (data not shown).
PCR products from SF-1-and DAX-1-positive tumor samples were extracted after agarose gel electrophoresis by adsorption to a silica-gel membrane, washing in high-salt buffer, and elution in 10 mmol/L TrisHCl (QIAGEN, West Sussex, UK). Purified PCR products were further analyzed by automated sequencing (ABI Prism, Perkin-Elmer Corp., Buckinghamshire, UK).
Hormone assays
LH, FSH, and TSH were measured using two-site chemiluminescent enzyme immunometric assays on the Immulite autoanalyzer (Euro/ DPC Limited, Gwyenedd, UK). The inter-and intraassay coefficients of variations for all these assays are less than 10% and 6%, respectively. Concentrations of ␣GSU were measured by a direct double-antibody RIA using antibodies purchased from UCB Bioproducts (Brussels, Belgium), chloramine-T-iodinated antigen (National Institute for Biological Standards and Control reagent 76/508, Potters Bar, Hertfordshire, UK) and calibrated against the first International Reference preparation 75/ 569 (National Institute for Biological Standards and Controls). Inter-and intraassay coefficients of variation were less than 11% and less than 6%, respectively. Cross-reactivities (in ng/ng) with purified LH, FSH, and TSH were 3.6%, 1.9%, and 1.3%, respectively. The detection limits of the above assays, defined as the concentration 2 sd above the response at zero dose, were as follows: LH, 0.4 IU/L; FSH, 0.6 IU/L; TSH, 0.008 mU/L; and ␣GSU, 0.1 g/L. All samples from each individual tumor were analyzed in the same assay, hormone data being expressed as the amount of hormone secreted per 24 h per 10 6 cells. After this normalization, the reported detection limits were as follows: LH, 2.0 mIU; FSH, 3.0 mIU; TSH, 0.1 U; and ␣GSU, 0.5 ng.
Statistical analysis
Comparisons between groups of tumors (see Figs. 2 and 3) were made using the Kruskal-Wallis test. Where the overall P-value was significant (P Ͻ 0.05), individual comparisons were made using Dunn's multiplecomparisons test. All statistical analysis was performed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). A value of P Ͻ 0.05 was taken as significant.
Results
Tumor tissue was initially collected from 56 patients, and adequate mRNA was obtained from 45, as judged by positive expression of GAPDH (18 somatotroph tumors, 7 prolactinomas, and 20 NFPAs). Four tumors were subsequently excluded because normal pituitary tissue was present on light microscopy or the tissue appeared necrotic; and in two cases, no tissue was available for histological examination. Two somatotroph tumors secreted PRL, but not GH, in vitro and were removed from subsequent analysis. Three NFPAs stained positively for GH and/or showed evidence of Pit-1 expression; these tumors were thought to represent silent somatotroph adenomas and were also excluded. Results are therefore presented on 34 tumors [13 somatotroph tumors (S1-S13), 4 prolactinomas (P1-P4), and 17 nonfunctioning adenomas (N1-N17)]. Table 1 shows both the immunocytochemical data and the in vitro secretion of gonadotropin hormones by 17 clinically nonfunctioning tumors. Within this group, 6 tumors stained positively for LH-␤ and/or FSH-␤ (tumors N1, N2, N3, N9, N10, and N12). Insufficient material was present from tumor N5 for immunocytochemical analysis of gonadotropin subunits. Tumors N4 and N11 were additionally diagnosed preoperatively as gonadotropin-secreting adenomas, on the basis of an elevated serum FSH (data not shown), although these tumors were negative, by immunocytochemistry, for gonadotropin ␤-subunits. These tumors (N1-N5 and N9 -N12) secreted LH and/or FSH in vitro in variable proportions. Tumors N6 -N8 and N13-N17 were negative (by immunocytochemistry), showed no more than trace amounts of hormone secretion in vitro, and were considered to represent null cell adenomas.
Immunocytochemistry and in vitro hormone secretion
All tumors from acromegalic patients were positive for GH, by immunocytochemistry, and 8 of 13 were additionally positive for PRL; PRL immunostaining was noted in 4 of 4 prolactinomas. LH-␤ and/or FSH-␤ were present in 4 somatotroph tumors (S1, S4, S10, and S11), whereas one acromegalic patient (tumor S3) had an elevated preoperative serum LH level (25.8 IU/L) with low/normal FSH (2.5 IU/L), suggesting in vivo neoplastic secretion. In vitro secretion of 
nd, Not determined; POS, positive; NEG, negative.
LH and/or FSH was observed in 4 somatotroph adenomas (S1, S2, S3, and S5). Figure 1 shows the PCR products generated using Pit-1, DAX-1, and SF-1 primers from a representative selection of tumors: S1, S2, S7, S8, S9, P1, N1, N2, N12, and N13. Positive expression of Pit-1, SF-1, and DAX-1 was demonstrated in cadaveric human pituitary, although the expression of DAX-1 and Pit-1 was weaker than observed in adenoma tissue. DAX-1 and SF-1 PCR products were subsequently gel-extracted and sequenced, in each case confirming the GenBank cDNA sequences (S74720 and U76388, respectively). Pit-1 expression was present in 12 of 13 somatotroph tumors tested, and was absent in all of the nonfunctioning tumors reported, further evidence against the presence of contaminating nontumorous elements. Tables 1 and 2 show the results of PCR for DAX-1 and SF-1. DAX-1 was present in 16 of 16 NFPAs, whereas SF-1 was present in 8 of 16 tumors. DAX-1 expression was found in 7 of 13 somatotroph tumors, whereas SF-1 mRNA was present in 4 of 12 somatotroph tumors. DAX-1 was present in none of the 4 prolactinomas studied, and SF-1 was present in only 1 of 4. Interestingly, DAX-1 and SF-1 expression tended to occur together in somatotroph adenomas (-square ϭ 4.3, P Ͻ 0.05). Figure 2 shows the in vitro secretion of LH, FSH, and ␣GSU by NFPAs and somatotroph adenomas, in relation to SF-1 expression, also demonstrated in Tables 1 and 2 . LH secretion was significantly greater in SF-1-positive NFPAs (median, 7.4 mIU/10 6 cells/24 h), compared with SF-1-negative tumors (median, Ͻ2.0 mIU/10 6 cells/24 h; P Ͻ 0.05). In contrast, FSH secretion was seen from NFPAs that were both SF-1-positive (median, 8.6 mIU/10 6 cells/24 h) and SF-1-negative (median, 3.1 mIU/10 6 cells/24 h). ␣GSU was also secreted equally in both SF-1-positive NFPAs (median, 1.4 ng/10 6 cells/24 h) and SF-1-negative tumors (median, 1.4 ng/10 6 cells/24 h). LH secretion was also noted in three somatotroph adenomas, all of which were SF-1-positive, whereas ␣GSU secretion by somatotroph adenomas occurred in both SF-1-positive and -negative tumors. Gonadotropin secretion, in relation to DAX-1 expression, is shown in Fig. 3 . All the NFPAs were positive for DAX-1. In vitro LH secretion (three tumors) and FSH secretion (two tumors) were observed only in somatotroph adenomas that were positive for DAX-1. ␣GSU secretion did not differ significantly between DAX-1-positive (median, 9.5 ng/10 6 cells/24 h) and -negative (median, 5.1 ng/10 6 cells/24 h) groups.
RT-PCR
Gonadotropin secretion, in relation to SF-1 and DAX-1 expression
Immunocytochemistry for DAX-1
To confirm the RT-PCR data, immunocytochemistry for DAX-1 was performed on 12 tumors, where sufficient tissue was available. The DAX-1 antibody gave clear nuclear staining on control sections of normal pituitary and in pituitary adenomas (see Fig. 4 ). Strongly positive staining was observed in 5 of 6 NFPAs tested (N8, N10, N11, N12, and N15 positive; N16 negative), all of which were shown to express DAX-1 mRNA. DAX-1-positive staining was also observed in 4 somatotroph adenomas (S3, S5, S6, and S7) that were DAX-1 mRNA-positive, and in one adenoma where DAX-1 mRNA was negative (S11). This discrepancy may indicate tumor heterogeneity, and it is worth noting that the sample for immunocytochemistry was positive for FSH-␤, whereas in vitro FSH secretion was not detected in the sample used for tissue culture and mRNA extraction. Somatotroph adenoma S12 was negative for both DAX-1 mRNA and protein. Taken together, the combined immunocytochemical and RT-PCR data suggest that the expression of DAX-1 is preferentially expressed in, but not restricted to, adenomas of gonadotroph origin.
Immunocytochemistry against SF-1, however, produced an unacceptable degree of nonspecific binding to control tissues, despite using previously published conditions (17) and sequential dilutions (data not shown).
Discussion
In this study, we have examined a large series of pituitary adenomas for the presence of the gonadotroph-specific orphan nuclear receptors, SF-1 and DAX-1, and related this to tumor type and to the in vitro expression of pituitary hormones. In vitro secretion of LH was restricted to tumors that were positive for SF-1, whereas secretion of neither FSH nor ␣GSU was related to the presence of SF-1. DAX-1 expression was demonstrated in all NFPAs but was also present in 7 of 17 GH-and/or PRL-secreting tumors and was not related to hormone secretion. By determining in vitro tumor hormone secretion, we have been able to gain a better insight into the protein synthetic capacity of adenomatous cells without the influence of hypothalamic factors, gonadal steroids, and the paracrine effects of surrounding pituitary tissue. Furthermore, we measured in vitro secretion and subsequently extracted mRNA from the same populations of dispersed tumor cells to avoid our results being confounded by heterogeneity within adenoma tissue.
Three previous studies have examined the expression of SF-1 in human pituitary adenomas. Ikuyama et al. (18) demonstrated SF-1 mRNA by Northern blotting in 5 of 13 NFPAs, and the authors noted an association between the expression of SF-1 and both FSH-␤ and ␣GSU, although they did not report on LH-␤ expression in that study. A subsequent paper by the same group demonstrated SF-1 positivity, by RT-PCR, in 12 of 18 NFPAs in association with LH-␤ and FSH-␤ expression (19) . Asa et al. (17) also used RT-PCR and identified SF-1 in 8 of 8 gonadotroph/null cell/oncocytomas. Our findings in NFPAs are in line with these investigators, but we have extended these observations to show that in vitro secretion of LH occurred predominantly in the NFPAs that were SF-1-positive. Whereas SF-1 is well established as a marker of gonadotroph differentiation (5), our data provide additional support to previous studies in cell lines and transgenic mice that have demonstrated that SF-1 is necessary for the expression of the LH-␤ gene (8, 29) . Interestingly, although the FSH-␤ promoter is less well characterized, there is evidence that FSH-␤ gene expression may not be regulated by SF-1 (30) , and indeed we failed to demonstrate an association between SF-1 expression and in vitro FSH secretion.
All of the gonadotroph and null cell adenomas in our series expressed DAX-1 mRNA. One previous study has addressed the expression of DAX-1 in pituitary adenomas, the authors demonstrating DAX-1 expression in 11 of 18 NFPAs, although they included a number of Pit-1-positive tumors that might be better considered as silent somatotroph adenomas (19) . DAX-1 was expressed in 7 of 8 tumors that they considered to be of gonadotroph lineage, where it was associated with the expression of gonadotroph-specific genes and with SF-1.
Human subjects with DAX-1 mutations and SF-1 (ftz-f1) disrupted mice exhibit abnormalities of gonadotropin synthesis and release (6, 31) . However, although SF-1 is a transcriptionally active protein in gonadotroph, adrenal, and gonadal tissues (32), DAX-1 has an inhibitory effect on SF-1-mediated transcription (15, 16) . At present, it seems likely that both SF-1 and DAX-1 are necessary for the initial differentiation of gonadotroph cells in man; whereas, in the mature cell, DAX-1 opposes the transcriptional effects of SF-1 (33) . Our data demonstrate that DAX-1 expression is not confined to pituitary adenomas of gonadotroph origin, and we were unable to demonstrate a clear relationship between DAX-1 expression and gonadotropin secretion.
In our series, SF-1 and DAX-1 mRNA were detectable in 33% and 54% of somatotroph tumors, respectively, frequently in association with in vitro gonadotropin secretion, gonadotropin immunoreactivity, and/or serum elevation of gonadotropins. The presence of DAX-1 protein in both NFPAs and somatotroph tumors was confirmed by immunocytochemistry. Previous studies have also demonstrated SF-1 in tumors of nongonadotroph origin. Asa et al. (17) documented SF-1 mRNA in a minority of corticotroph, lactotroph, and somatotroph adenomas. In one of the corticotroph adenomas, the expression of SF-1 was diffuse and associated with LH-␤ immunostaining. More frequently, adenomas exhibited foci of SF-1 positivity in association with gonadotropin hormones, and the authors were inclined to view these as nests of normal cells within the adenoma. This explanation is hard to reconcile with earlier work that has repeatedly demonstrated monoclonality in the majority of pituitary tumors (34). Ikuyama et al. (18) were able to demonstrate SF-1 mRNA in sufficient quantities to be demonstrated by Northern blot analysis in one of seven somatotroph tumors; this tumor also expressed FSH-␤. The one previous study looking at DAX-1 expression did not identify DAX-1 mRNA in somatotroph adenomas, but the authors highlighted three of the clinically nonfunctioning tumors studied that expressed both Pit-1 and DAX-1 mRNA (19) . Electron microscopy of these tumors was not reported, but it is possible that they were silent subtype III (plurihormonal) adenomas (35) .
Our findings and those of previous investigators strongly suggest that a minority of tumors from patients presenting with acromegaly express hormones and transcription factors that are specific to gonadotroph cells in the normal pituitary. It is likely that the expression of SF-1 and DAX-1 and the in vitro secretion of gonadotropin hormones indicate a process of tumor dedifferentiation into pluripotent cells.
␣GSU secretion in vitro was not significantly greater in SF-1-positive NFPAs or somatotroph tumors, compared with SF-1-negative tumors. Ikuyama et al. (18) and Asa et al. (17) also demonstrated ␣GSU expression in somatotroph adenomas in the absence of SF-1. ␣GSU is expressed in the fetal pituitary in advance of SF-1 expression and gonadotroph determination and is present, albeit in reduced quantities, in the FTZ-F1-disrupted (SF-1 knockout) mouse (6) . The ␣GSU gene is expressed in thyrotroph and placental cells, as well as in gonadotroph cells, and ␣GSU-secreting murine thyrotroph and human choriocarcinoma cell lines do not express SF-1; ␣GSU promoter activity is determined by cis-elements other than the SF-1 binding site in these models (36) . It is evident that there are a number of different mechanisms that can lead to tissue-specific expression of the ␣GSU gene.
␣GSU expression may arise in SF-1-negative tumors because of loss of expression of a repressor protein or through altered regulation of the ␣GSU promoter; indeed, a recent report has suggested that the ␣GSU promoter contains a cis-element that can act as a repressor in the GH3 somatotroph cell line (37) . However, we have previously demonstrated that ␣GSU secretion is strongly correlated with that of TSH in somatotroph adenomas (25) , and it may be that thyrotroph-specific factors account for the presence of ␣GSU in SF-1-negative ␣GSU-secreting cells in somatotroph tumors. It is of interest that ␣GSU secretion in the somatotroph adenomas that were SF-1 negative frequently occurred in association with in vitro TSH secretion, as shown in Table 2 .
In summary, our studies have demonstrated that in pituitary adenomas of gonadotroph origin, DAX-1 was present in all cases, but the expression of SF-1 was found in only 50%, where it was positively associated with LH secretion. In somatotroph adenomas, SF-1 and DAX-1 expression were demonstrated in a smaller proportion; but in these tumors, there was an association with the in vitro secretion of LH. Previous studies have suggested that SF-1 and DAX-1 expression is restricted to cells of gonadotroph lineage (17) (18) (19) . The expression of these factors in pituitary adenomas from patients presenting with acromegaly supports the hypothesis that some adenomas may dedifferentiate into, or arise from, a common gonadotroph/somatotroph precursor.
